Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Metastatic Solid Tumors
Clinical trial register · United States · industry-sponsored

Metastatic Solid Tumors Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9140 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 20 Oct 2026, 03:16 UTC
9140
Studies in scope
industry-sponsored, all four open statuses
4969
Recruiting now
open to new participants
2198
Lead sponsors
across recruiting studies
Top states
California 10 Texas 7 Colorado 6 Massachusetts 6 Florida 5
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Metastatic Solid Tumors trials in the USA

17 of 9140 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Solve Therapeutics
Phase 1
70
California
2026-08-04
Recruiting
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
NCT07397338Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC), NSCLC
Revolution Medicines, Inc.
Phase 1/2
370
California, Connecticut, Minnesota, Tennessee, Texas, Virginia
2026-01-30
Recruiting
New Phase Ltd.
Not applicable
12
Minnesota
2025-12-16
Recruiting
A Study of DS3610a in Participants With Advanced Solid Tumor
NCT07159126Solid Tumors, Metastatic Solid Tumors
Daiichi Sankyo
Phase 1
70
Wisconsin
2025-10-09
Recruiting
Avenzo Therapeutics, Inc.
Phase 1/2
355
California, Colorado, Connecticut, Florida, Massachusetts, New York, North Carolina, Ohio
2025-10-02
Recruiting
SLV-324 Treatment of Metastatic Solid Tumors
NCT07108114Metastatic Solid Tumors
Solve Therapeutics
Phase 1
70
California, Missouri, Ohio, Pennsylvania, Texas, Washington
2025-08-25
Recruiting
Erasca, Inc.
Phase 1
200
Tennessee, Texas, Washington
2025-08-06
Recruiting
Erasca, Inc.
Phase 1
600
California, Colorado, Florida, Massachusetts, New York, Texas, Virginia
2025-06-05
Recruiting
Avenzo Therapeutics, Inc.
Phase 1/2
480
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Massachusetts
2025-06-04
Active, closed
Daiichi Sankyo
Phase 2
335
Georgia, Michigan, New Jersey, New York, Tennessee, Texas
2025-01-06
Recruiting
Trutino Biosciences Inc.
Phase 1
50
Arizona
2024-12-30
Active, closed
Genentech, Inc.
Phase 1
65
Alabama, Connecticut, New York, Ohio, Pennsylvania, Tennessee
2023-11-27
Recruiting
Incyte Corporation
Phase 1
570
California, Massachusetts, Michigan, New Jersey, New York, Pennsylvania, Rhode Island, Texas
2023-07-24
Active, closed
Merck Sharp & Dohme LLC
Phase 1
95
Illinois, Kentucky, New Jersey
2023-07-06
Recruiting
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
NCT04094610Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma, Primary CNS Tumors
Turning Point Therapeutics, Inc.
Phase 1/2
75
California, Colorado, Florida, Georgia, Maine, Massachusetts, Missouri, New Jersey
2020-03-12
Active, closed
Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET
NCT03993873Advanced Solid Tumor, Metastatic Solid Tumors, MET Gene Alterations
Turning Point Therapeutics, Inc.
Phase 1
95
California, Colorado, Illinois, Massachusetts, Michigan, Missouri, Ohio, Texas
2019-09-05
Recruiting
Turning Point Therapeutics, Inc.
Phase 1/2
500
California, Colorado, District of Columbia, Florida, Georgia, Illinois, Louisiana, Maryland
2017-03-07
Rows per page Showing 1–17 of 17
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 20 October 2026. https://priyalifescience.com/clinical-trials-usa/condition/metastatic-solid-tumors

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,140 studies in total at the last sync on 20 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 17 of those studies listing the condition Metastatic Solid Tumors.

How many Metastatic Solid Tumors trials are recruiting in the US?

13 of the 17 studies on this page are recruiting new participants as of the 20 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 4 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Metastatic Solid Tumors), 17 studies
PhaseStudiesRecruitingShare
Phase 110758.8%
Phase 1/25529.4%
Not applicable115.9%
Phase 2105.9%

Most active sponsors

Lead sponsors with the most studies (Metastatic Solid Tumors)
Lead sponsorStudiesRecruiting
Turning Point Therapeutics, Inc.32
Avenzo Therapeutics, Inc.22
Daiichi Sankyo21
Erasca, Inc.22
Solve Therapeutics22
Genentech, Inc.10
Incyte Corporation11
Merck Sharp & Dohme LLC10
New Phase Ltd.11
Revolution Medicines, Inc.11

Top states

Top states (Metastatic Solid Tumors), by number of studies with a site there
StateStudies
California10
Texas7
Colorado6
Massachusetts6
Florida5
New York5
Connecticut4
Georgia4
New Jersey4
Ohio4
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.